$STOK
Stoke Therapeutics, Inc. Stock $stok

$stok Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000156459023003175 Filed on March 06, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$5.152M	$3.268M	$12.41M
YoY Change	71.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.21M	$9.384M	$38.92M
YoY Change	7.64%	7.57%	22.03%
% of Gross Profit
Research & Development	$19.63M	$21.06M	$77.84M
YoY Change	7.22%	33.27%	43.7%
% of Gross Profit
Depreciation & Amortization	$597.0K	$609.0K	$1.500M
YoY Change	141.7%	159.15%	50.0%
% of Gross Profit
Operating Expenses	$29.84M	$30.44M	$116.8M
YoY Change	7.36%	24.13%	35.67%
Operating Profit	-$24.69M		-$104.4M
YoY Change	-0.42%		21.25%
Interest Expense	$2.103M	$1.479M	$3.122M
YoY Change	1922.12%	4008.33%	2501.67%
% of Operating Profit
Other Income/Expense, Net	$2.145M	$42.00K	$3.289M
YoY Change	1369.18%	0.0%	1165.0%
Pretax Income	-$22.55M	-$25.66M	-$101.1M
YoY Change	-8.54%	4.94%	17.79%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$22.55M	-$25.66M	-$101.1M
YoY Change	-8.54%	4.94%	17.79%
Net Earnings / Revenue	-437.6%	-785.04%	-814.73%
Basic Earnings Per Share	-$0.53		-$2.60
Diluted Earnings Per Share	-$0.53	-$0.65	-$2.60
COMMON SHARES
Basic Shares Outstanding	44.15M	39.43M	38.90M
Diluted Shares Outstanding	42.54M		38.90M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$253.7M	$229.6M	$229.6M
YoY Change	-13.49%	4.45%	4.45%
Cash & Equivalents	$190.3M	$113.6M	$113.6M
Short-Term Investments	$63.33M	$116.0M	$116.0M
Other Short-Term Assets	$5.880M	$2.955M	$13.89M
YoY Change	-52.16%	-68.14%	49.71%
Inventory
Prepaid Expenses	$10.19M	$10.93M
Receivables
Other Receivables
Total Short-Term Assets	$270.2M	$244.1M	$244.1M
YoY Change	-11.62%	6.48%	6.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.789M	$6.675M	$11.43M
YoY Change	-29.27%	61.27%	25.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$569.0K	$569.0K	$569.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$11.56M	$12.00M	$12.00M
YoY Change	13.7%	24.36%	24.36%
TOTAL ASSETS
Total Short-Term Assets	$270.2M	$244.1M	$244.1M
Total Long-Term Assets	$11.56M	$12.00M	$12.00M
Total Assets	$281.8M	$256.1M	$256.1M
YoY Change	-10.81%	7.2%	7.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.299M	$766.0K	$766.0K
YoY Change	29.18%	-67.88%	-67.88%
Accrued Expenses	$13.27M	$15.24M	$15.24M
YoY Change	25.38%	7.21%	7.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$31.53M	$31.39M	$31.39M
YoY Change	37.64%	83.17%	83.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.303M	$2.968M	$39.82M
YoY Change	-95.66%	-24.84%	908.46%
Total Long-Term Liabilities	$36.45M	$39.82M	$39.82M
YoY Change	-31.3%	908.46%	908.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.53M	$31.39M	$31.39M
Total Long-Term Liabilities	$36.45M	$39.82M	$39.82M
Total Liabilities	$67.97M	$71.22M	$71.22M
YoY Change	-10.51%	237.72%	237.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$319.7M	-$297.2M
YoY Change		51.54%
Common Stock	$4.000K	$4.000K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$213.8M	$184.8M	$184.8M
YoY Change
Total Liabilities & Shareholders Equity	$281.8M	$256.1M	$256.1M
YoY Change	-10.81%	7.2%	7.2%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$22.55M	-$25.66M	-$101.1M
YoY Change	-8.54%	4.94%	17.79%
Depreciation, Depletion And Amortization	$597.0K	$609.0K	$1.500M
YoY Change	141.7%	159.15%	50.0%
Cash From Operating Activities	-$21.36M	-$22.37M	-$31.87M
YoY Change	-165.73%	37.61%	-52.37%
INVESTING ACTIVITIES
Capital Expenditures	$165.0K	$409.0K	$3.962M
YoY Change	-80.38%	-301.48%	230.17%
Acquisitions
YoY Change
Other Investing Activities	$53.25M	$22.90M	-$41.92M
YoY Change	-139.46%	90.83%	-44.27%
Cash From Investing Activities	$53.09M	$22.49M	-$45.88M
YoY Change	-139.1%	90.64%	-39.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	45.05M	43.00K	46.41M
YoY Change	5.99%	-74.85%	3514.41%
NET CHANGE
Cash From Operating Activities	-21.36M	-22.37M	-31.87M
Cash From Investing Activities	53.09M	22.49M	-45.88M
Cash From Financing Activities	45.05M	43.00K	46.41M
Net Change In Cash	76.78M	160.0K	-31.34M
YoY Change	-174.34%	-103.73%	-77.94%
FREE CASH FLOW
Cash From Operating Activities	-$21.36M	-$22.37M	-$31.87M
Capital Expenditures	$165.0K	$409.0K	$3.962M
Free Cash Flow	-$21.52M	-$22.78M	-$35.83M
YoY Change	-168.0%	41.9%	-47.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	117000
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	588000
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	132000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	244070000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	229218000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	569000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	569000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4753000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4939000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6675000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4139000
CY2022Q4	us-gaap	Assets Assets	256067000
CY2021Q4	us-gaap	Assets Assets	238865000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	766000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2385000
CY2022Q4	stok	Accrued And Other Current Liabilities AccruedAndOtherCurrentLiabilities	15748000
CY2021Q4	stok	Accrued And Other Current Liabilities AccruedAndOtherCurrentLiabilities	14754000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14880000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31394000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17139000
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	36856000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2968000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3949000
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	39824000
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3949000
CY2022Q4	us-gaap	Liabilities Liabilities	71218000
CY2021Q4	us-gaap	Liabilities Liabilities	21088000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39439575
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39439575
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36902499
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36902499
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	483170000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	414024000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1175000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-168000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-297150000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196083000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	184849000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	217777000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	256067000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	238865000
CY2022	us-gaap	Revenues Revenues	12405000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	77837000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54168000
CY2022	us-gaap	Operating Expenses OperatingExpenses	116761000
CY2021	us-gaap	Operating Expenses OperatingExpenses	86065000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-104356000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-86065000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	167000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	140000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3289000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	260000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.60
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.60
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.34
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38897442
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38897442
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36739269
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36739269
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-85805000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1007000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-168000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1007000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-168000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-102074000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85973000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	286078000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-168000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16450000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	777000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	509000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-85805000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	217777000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1007000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22854000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	494000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	570000
CY2022	stok	Stock Issued During Period Value Shares Sold At Market StockIssuedDuringPeriodValueSharesSoldAtMarket	45228000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-101067000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	184849000
CY2022	us-gaap	Profit Loss ProfitLoss	-101067000
CY2021	us-gaap	Profit Loss ProfitLoss	-85805000
CY2022	us-gaap	Depreciation Depreciation	1546000
CY2021	us-gaap	Depreciation Depreciation	974000
CY2022	stok	Amortization And Accretion Of Marketable Securities AmortizationAndAccretionOfMarketableSecurities	-211000
CY2021	stok	Amortization And Accretion Of Marketable Securities AmortizationAndAccretionOfMarketableSecurities	143000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22854000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	16450000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29000
CY2022	stok	Reduction In Carrying Amount Of Operating Lease Right Of Use Assets ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets	1989000
CY2021	stok	Reduction In Carrying Amount Of Operating Lease Right Of Use Assets ReductionInCarryingAmountOfOperatingLeaseRightOfUseAssets	1256000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5183000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2851000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3530000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2897000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	51736000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31866000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66907000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3962000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1200000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	201320000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	87226000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	159400000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	12000000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45882000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76426000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	494000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	777000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	570000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	509000
CY2022	stok	Proceeds From Controlled Equity Offering Sales Agreement ProceedsFromControlledEquityOfferingSalesAgreement	45344000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-2000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1284000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	145464000
CY2022	stok	Right Of Use Assets Recognized In Exchange For Operating Leases RightOfUseAssetsRecognizedInExchangeForOperatingLeases	1802000
CY2021	stok	Right Of Use Assets Recognized In Exchange For Operating Leases RightOfUseAssetsRecognizedInExchangeForOperatingLeases	5081000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1267000
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2018Q4	stok	Number Of Renewal Option To Extend Operating Lease Terms NumberOfRenewalOptionToExtendOperatingLeaseTerms	1
CY2018Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2018Q4	stok	Operating Lease Cost Per Year OperatingLeaseCostPerYear	200000
CY2018Q4	stok	Annual Base Rent Increase Percentage For Operating Lease AnnualBaseRentIncreasePercentageForOperatingLease	0.025
CY2018Q4	stok	Operating Lease Commencement Date OperatingLeaseCommencementDate	2019-05-01
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4286461
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.70
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18454000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.32
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.07
CY2022	stok	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	35700000
CY2021	stok	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	44700000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9900000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22900000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16500000
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	53300000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y9M18D
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.34
CY2022Q2	dei	Entity Public Float EntityPublicFloat	297000000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46409000
CY2022	dei	Entity Registrant Name EntityRegistrantName	Stoke Therapeutics, Inc.
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31897000
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Bedford
CY2022	dei	Trading Symbol TradingSymbol	STOK
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44147687
CY2022	dei	Auditor Firm AuditorFirmId	185
CY2022	dei	Auditor Name AuditorName	KPMG LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, MA USA
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144895000
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	45 Wiggins Ave
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01730
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-101067000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-85805000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3459500
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38924000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31339000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-142049000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	287513000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	114125000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	145464000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	121000
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3122000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	120000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-101067000
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001623526
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0415
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0151
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0182
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0078
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.70
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.70
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.73
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38938
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1144582
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	City Area Code CityAreaCode	781
CY2022	dei	Local Phone Number LocalPhoneNumber	430-8200
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113556000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	116039000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	74915000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6943000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2955000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10932000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2216000
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, expenses and disclosure of contingent assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. </p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113556000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144895000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	569000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	569000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	114125000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	145464000
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at an accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p>
CY2022	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue recognition</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue in accordance with ASC Topic 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (“ASC 606”). This standard applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2022, the Company entered into a collaboration and licensing agreement with Acadia Pharmaceuticals, Inc. (“Acadia”) which is within the scope of ASC 606 (see Note 8). In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under this agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for this arrangement, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described. The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company’s consolidated balance sheets. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Upfront license fees</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licenses of the Company’s intellectual property granted to Acadia was not determined to be distinct from the other promises or performance obligations identified in the arrangement. Accordingly, such licenses are therefore combined with other promises in the arrangement. The Company exercises judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Customer options</span></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. No such material rights were identified in the arrangement with Acadia. If such material rights were identified, then the Company would allocate the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized or begin to be recognized as revenue until, at the earliest, the option is exercised. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and development services</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The promises under the Company’s collaboration agreement with Acadia includes research and development services to be performed by the Company for or on behalf of the customer. Payments or reimbursements resulting from the Company’s research and development efforts are recognized as the services are performed and presented on a gross basis because the Company is the principal for such efforts. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of the Acadia arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The development milestones in the Acadia arrangement are not considered probable of achievement at the outset of the arrangement.</p>
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	117214000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1175000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	116039000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	75083000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	168000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	74915000
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10882000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6800000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4207000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2661000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6675000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4139000
CY2022	us-gaap	Depreciation Depreciation	1500000
CY2021	us-gaap	Depreciation Depreciation	1000000.0
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5754000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5383000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	525000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	523000
CY2022Q4	stok	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	6601000
CY2021Q4	stok	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	6801000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2359000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1507000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	509000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	540000
CY2022Q4	stok	Accrued And Other Current Liabilities AccruedAndOtherCurrentLiabilities	15748000
CY2021Q4	stok	Accrued And Other Current Liabilities AccruedAndOtherCurrentLiabilities	14754000
CY2018Q3	stok	Annual Base Rent Increase Percentage For Operating Lease AnnualBaseRentIncreasePercentageForOperatingLease	0.03
CY2018Q3	stok	Operating Lease Commencement Date OperatingLeaseCommencementDate	2018-12-10
CY2018Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2018Q4	stok	Area Of Space Subject To Operating Lease AreaOfSpaceSubjectToOperatingLease	2485
CY2018Q3	stok	Area Of Space Subject To Operating Lease AreaOfSpaceSubjectToOperatingLease	23000
CY2018Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2018Q3	stok	Operating Lease Cost Per Year OperatingLeaseCostPerYear	900000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2532000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2608000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	173000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5313000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	237000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5076000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4753000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4939000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2359000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1507000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2717000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3532000
CY2022Q4	stok	Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted	5076000
CY2021Q4	stok	Operating Lease Liability Excluding Leases Entered Access Yet To Be Granted OperatingLeaseLiabilityExcludingLeasesEnteredAccessYetToBeGranted	5039000
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0469
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3459500
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1311897
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5435304
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.77
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	64981000
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.97
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	270376
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.83
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	254450
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	29.77
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	95331
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	34.72
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8274647
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.28
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20598000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22854000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16450000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-101067000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-85805000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38897442
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38897442
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36739269
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36739269
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.60
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.60
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.34
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.34
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.074
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.004

Files In Submission

Name	View Source	Status
0001564590-23-003175-index-headers.html	Edgar Link	pending
0001564590-23-003175-index.html	Edgar Link	pending
0001564590-23-003175.txt	Edgar Link	pending
0001564590-23-003175-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gxvi1ukevnig000001.jpg	Edgar Link	pending
gxvi1ukevnig000002.jpg	Edgar Link	pending
gxvi1ukevnig000003.jpg	Edgar Link	pending
gxvi1ukevnig000004.jpg	Edgar Link	pending
gxvi1ukevnig000005.jpg	Edgar Link	pending
gxvi1ukevnig000006.jpg	Edgar Link	pending
gxvi1ukevnig000007.jpg	Edgar Link	pending
gxvi1ukevnig000008.jpg	Edgar Link	pending
gxvi1ukevnig000009.jpg	Edgar Link	pending
gxvi1ukevnig000010.jpg	Edgar Link	pending
gxvi1ukevnig000011.jpg	Edgar Link	pending
gxvi1ukevnig000012.jpg	Edgar Link	pending
gxvi1ukevnig000013.jpg	Edgar Link	pending
gxvi1ukevnig000014.jpg	Edgar Link	pending
gxvi1ukevnig000015.jpg	Edgar Link	pending
gxvi1ukevnig000016.jpg	Edgar Link	pending
gxvi1ukevnig000017.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
stok-20221231_cal.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stok-10k_20221231.htm	Edgar Link	pending
stok-10k_20221231_htm.xml	Edgar Link	pending
stok-20221231.xsd	Edgar Link	pending
stok-ex103_52.htm	Edgar Link	pending
stok-ex231_205.htm	Edgar Link	pending
stok-ex311_9.htm	Edgar Link	pending
stok-ex312_7.htm	Edgar Link	pending
stok-ex321_10.htm	Edgar Link	pending
stok-ex322_6.htm	Edgar Link	pending
stok-20221231_def.xml	Edgar Link	unprocessable
stok-20221231_lab.xml	Edgar Link	unprocessable
stok-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STOK
Stoke Therapeutics, Inc. Stock $stok

2023 Q1 Form 10-K Financial Statement

#000156459023003175 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STOK Stoke Therapeutics, Inc. Stock $stok

2023 Q1 Form 10-K Financial Statement

#000156459023003175 Filed on March 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STOK
Stoke Therapeutics, Inc. Stock $stok